Alessandra Arcelli1, Alessandra Guido1, Milly Buwenge2, Nicola Simoni3, Renzo Mazzarotto3, Gabriella Macchia4, Francesco Deodato4, Savino Cilla5, Pierluigi Bonomo6, Valerio Scotti7, Liliana Belgioia8, Giorgio Tolento1, Francesco Cellini9, Elisa Grassi10, Mariacristina DI Marco10, Riccardo Casadei11, Alessio G Morganti1, Silvia Cammelli1. 1. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. 2. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy mbuwenge@gmail.com. 3. Radiotherapy Unit, Azienda Ospedaliera Universitaria, Verona, Italy. 4. Radiotherapy Unit, 'Giovanni Paolo II' Foundation, Catholic University of Sacred Heart, Campobasso, Italy. 5. Medical Physic Unit, 'Giovanni Paolo II' Foundation, Catholic University of Sacred Heart, Campobasso, Italy. 6. Radiation Oncology Unit, Department of Experimental and Clinical Biomedical Sciences, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Florence, Italy. 7. San Rossore Private Hospital, Pisa, Italy. 8. Department of Radiotherapy, Policlinico San Martino, University of Genoa, Genoa, Italy. 9. Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy. 10. Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. 11. Department of Medical and Surgical Sciences - DIMEC, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.
Abstract
AIM: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters' impact on these outcomes was assessed. MATERIALS AND METHODS: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. RESULTS: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). CONCLUSION: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC. Copyright
AIM: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters' impact on these outcomes was assessed. MATERIALS AND METHODS: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. RESULTS: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). CONCLUSION: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC. Copyright
Authors: Christelle Bouchart; Jean-Luc Engelholm; Jean Closset; Julie Navez; Patrizia Loi; Yeter Gökburun; Thierry De Grez; Laura Mans; Alain Hendlisz; Maria Antonietta Bali; Pierre Eisendrath; Dirk Van Gestel; Matthieu Hein; Luigi Moretti; Jean-Luc Van Laethem Journal: Ther Adv Med Oncol Date: 2021-10-19 Impact factor: 8.168
Authors: William A Hall; Christina Small; Eric Paulson; Eugene J Koay; Christopher Crane; Martijn Intven; Lois A Daamen; Gert J Meijer; Hanne D Heerkens; Michael Bassetti; Stephen A Rosenberg; Katharine Aitken; Sten Myrehaug; Laura A Dawson; Percy Lee; Cihan Gani; Michael David Chuong; Parag J Parikh; Beth A Erickson Journal: Front Oncol Date: 2021-05-11 Impact factor: 5.738
Authors: Alessandra Arcelli; Milly Buwenge; Gabriella Macchia; Federica Bertini; Alessandra Guido; Francesco Deodato; Savino Cilla; Valerio Scotti; Maria Elena Rosetto; Igor Djan; Salvatore Parisi; Gian Carlo Mattiucci; Francesco Cellini; Michele Fiore; Pierluigi Bonomo; Liliana Belgioia; Rita Marina Niespolo; Pietro Gabriele; Mariacristina Di Marco; Nicola Simoni; Renzo Mazzarotto; Alessio Giuseppe Morganti Journal: Cancer Med Date: 2020-09-10 Impact factor: 4.452